AMCX Earnings

AMCX reported its FY2025Q3 earnings on 2025-11-07, showcasing a revenue of 561.74M against an estimate of 549.26M, resulting in a 2.27% surprise. The EPS was 0.18, surpassing the expected 0.31 by -41.94%. The stock experienced a 3.72% price change on the earnings day and a 13.38% change over the next five days, reflecting market reactions to the results.

Following AMCX's FY2025Q3 earnings announcement on 2025-11-07, the stock price moved by 3.72% on the day of the release. Over the subsequent five days, it saw a 13.38% change. Historically, AMCX's stock price tends to shift by an average of 2.05% in the 10 days leading up to earnings and -1.95% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate AMCX's annual revenue to reach 548.86M, while the EPS is projected at 0.51. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AMCX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AMCX's stock price typically moves by 2.05% in the 10 days before its earnings and -1.95% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.51 and revenue of 548.86M.

The earnings call summary presents a mixed picture. Strong streaming revenue growth and share repurchases are positive, but high net debt, declining international and advertising revenues, and economic uncertainties weigh negatively. The Q&A session revealed management's optimism in streaming and advertising, but lacked clarity on key issues like The Walking Dead rights. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement.